Targeted Chemotherapy of Visceral Leishmaniasis by Lactoferrin-Appended Amphotericin B-Loaded Nanoreservoir:
 In Vitro
 and
 In Vivo
 Studies.

Asthana, Shalini; Gupta, Pramod; Jaiswal, Anil K.; Dube, Anuradha; Chourasia, Manish K.

doi:10.2217/nnm.14.182

Cited by 42 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reduction of zeta potential may be related to the encapsulation of AmB, which was identical to that of the previous studies. 41 Although zeta potential of drug-loaded micelles was lower than that of blank micelles, they all presented good dispersion and stability during the period of the experiment. Figure 2C exhibits the morphological observation of AmB/ …”

Section: Preparation and Characterization Of Micellesmentioning

confidence: 93%

Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral Candida albicans

Zhou¹,

Zhang²,

Chen³

et al. 2017

IJN

View full text Add to dashboard Cite

Fatal Candida albicans infections in the mucosal system can occur in association with immune-compromised diseases and dysbacteriosis. Currently, amphotericin B (AmB) is considered to be the most effective antibiotic in the treatment of C. albicans infections, but its clinical application is limited by side effects and poor bioavailability. In order to use AmB in the local treatment of oral C. albicans infections, AmB/MPEG-PCL-g-PEI (monomethoxy poly(ethylene glycol)-poly(epsilon-caprolactone)-graft-polyethylenimine, MPP) micelles were prepared. A series of characterizations were performed. The micelles allowed a sustained in vitro release in both normal oral conditions (pH 6.8) and C. albicans infection conditions (pH 5.8). Then, buccal tablets containing freeze-dried powder of AmB/MPP micelles were produced by direct compression process and evaluated as regards to weight variation, hardness, and friability. In vitro drug release of the buccal tablets was measured in both the United States Pharmacopeia dissolution apparatus and the dissolution rate test apparatus, which was previously designed for simulating in vivo conditions of the oral cavity. The buccal tablets could sustainably release within 8 h and meet the antifungal requirements. Regarding safety assessment of AmB/MPP micelles, in vivo histopathological data showed no irritation toward buccal mucosa of the rats in both optical microscopy and ultrastructure observation of the tissues. MTT experiment proved that AmB/MPP micelles reduced the cytotoxicity of AmB. The micelles delivered through the gastrointestinal route were also found to be non-systemic toxicity by liquid chromatography-mass spectrometry analysis. Furthermore, the antifungal action of AmB/MPP micelles was evaluated. Although AmB/MPP had no obvious improvement as compared to AmB alone in the antifungal effect on planktonic C. albicans , the micelles significantly enhanced the antifungal activity against the biofilm state of C. albicans . Thus, it was concluded that AmB/MPP micelles represent a promising novel drug delivery system for the local treatment of oral C. albicans infections.

show abstract

Section: Preparation and Characterization Of Micellesmentioning

confidence: 93%

Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral Candida albicans

Zhou¹,

Zhang²,

Chen³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…This approach may also be applicable for spleen selective drug targeting as splenic macrophages actively phagocytose red blood cells during hypersplenism and liver cirrhosis [84]. Research into the targeting of splenic and liver Leishmaniasis infections using nanoparticles may also be of potential strategic use [85, 86]. Standardized studies in animal models and pre-clinical trials measuring the efficacies of nanoparticle-based therapeutic agents will also be required for the development of novel spleen-selective therapeutic agents.…”

Section: Targeting Spleen For the Treatment Of Liver Cirrhosismentioning

confidence: 99%

The spleen in liver cirrhosis: revisiting an old enemy with novel targets

et al. 2017

View full text Add to dashboard Cite

The spleen is a secondary lymphoid organ which can influence the progression of multiple diseases, notably liver cirrhosis. In chronic liver diseases, splenomegaly and hypersplenism can manifest following the development of portal hypertension. These splenic abnormalities correlate with and have been postulated to facilitate the progression of liver fibrosis to cirrhosis, although precise mechanisms remain poorly understood. In this review, we summarize the literature to highlight the mechanistic contributions of splenomegaly and hypersplenism to the development of liver cirrhosis, focusing on three key aspects: hepatic fibrogenesis, hepatic immune microenvironment dysregulation and liver regeneration. We conclude with a discussion of the possible therapeutic strategies for modulating splenic abnormalities, including the novel potential usage of nanomedicine in non-surgically targetting splenic disorders for the treatment of liver cirrhosis.

show abstract

“…Leishmania promastigotes use surface reductase at the time of ferric iron reduction to give access to the ferrous form. Previous studies have affirmed that the L. chagasi promastigote forms can use lactoferrin and transferrin iron for growth and metabolism (17)(18)(19). The findings have also suggested that the promastigote form has specific locations for connection between lactoferrin and transferrin.…”

Section: Discussionmentioning

confidence: 88%

“…Lactoferrin bonded with amphotericin B along with the LcfPGNP-AmB nanoparticle has anti-leishmaniasis effects, which decreases parasite burden in the spleen and increases immunity in the hamster. Iron is an essential nutrient for pathogen survival in the host cell (17)(18)(19). As a general strategy against microbes in mammals, the inhibitor complex system of iron has evolved to reduce the microbes access to iron.…”

Section: Discussionmentioning

confidence: 99%

Assessment of the Effect of Lactoferrin on Promastigote and Amastigote Forms of Leishmania major In Vitro

Baroogh

Khanaliha

Maleki

et al. 2019

Jundishapur J Microbiol

View full text Add to dashboard Cite

Background: Today, most patients with cutaneous leishmaniasis are treated with drugs such as glucantime; however, severe drug resistance to these drugs is found, in addition to recurrence, extensive drug complications, and secondary infections in many patients. Objectives: Therefore, due to the lack of sufficient information on this subject, this study was undertaken for the first time to investigate the antimicrobial activity of multifunctional lactoferrin as one of the most important bioactive compounds on amastigotes and promastigotes forms of Leishmania major in vitro. Methods: In this study, six concentrations of lactoferrin (2.5, 5, 10, 20, 40, and 80 µg/mL) were added to parasite cultures at specified times. The MTT was done. Leishmania major promastigotes were incorporated to J774 cells and then incubated for 72 hours. The results were compared with the results of glucantime, as a standard. In the end, flow cytometry was performed to investigate apoptosis. Results: After 24, 48, and 72 hours of incubation in the presence of various concentrations of lactoferrin, the number of amastigotes and promastigote parasites increased over time without any significant difference compared to the control group (P > 0.05), but it was significant compared to glucantime at the 80 µg/mL concentration (P < 0.05). Besides, lactoferrin showed very low toxicity effects on macrophages and stimulated the growth of both forms of L. major parasite. Conclusions: Our findings indicated that lactoferrin could not induce early and late apoptosis in both forms of L. major.

show abstract

Targeted Chemotherapy of Visceral Leishmaniasis by Lactoferrin-Appended Amphotericin B-Loaded Nanoreservoir: In Vitro and In Vivo Studies.

Abstract: Superior efficacy, desired stability and reliable safety of cost-effective LcfPGNP-AmB, suggest its potential for leishmaniasis therapeutics.

Cited by 42 publications

References 27 publications

Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral <em>Candida albicans</em>

Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral <em>Candida albicans</em>

The spleen in liver cirrhosis: revisiting an old enemy with novel targets

Assessment of the Effect of Lactoferrin on Promastigote and Amastigote Forms of Leishmania major In Vitro

Contact Info

Product

Resources

About